News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
244 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37190)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53929)
2023 (42568)
2024 (38485)
2025 (24804)
Month
January (4152)
February (4569)
March (4908)
April (4902)
May (5255)
June (4735)
July (4593)
August (4725)
September (5112)
October (5032)
November (5368)
December (4315)
Day
1 (2)
2 (10)
3 (262)
4 (319)
5 (322)
6 (403)
7 (138)
8 (5)
9 (6)
10 (288)
11 (270)
12 (233)
13 (253)
14 (122)
15 (4)
16 (3)
17 (180)
18 (202)
19 (174)
20 (201)
21 (97)
22 (2)
23 (5)
24 (187)
25 (247)
26 (232)
27 (214)
28 (80)
29 (13)
30 (7)
31 (244)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Harbour BioMed Will Present Its New Platform HBICE (Heavy chain only antibody (HCAb) Based Immune Cell Engager) at 16th PEGS Boston Summit
Harbour BioMed, a global, clinical-stage, innovative biopharmaceutical company, today announced that it presented its newly developed HBICE TM (HCAb Based Immune Cell Engager) platform and its ability to generate fast and reliable next-generation bispecific antibodies for immunotherapies at the 16th PEGS Boston Summit. The poster will
August 31, 2020
·
3 min read
Positive headline results from the Vyepti (eptinezumab-jjmr) RELIEF study
Initiating VYEPTI™ (eptinezumab-jjmr) migraine prevention during a migraine attack demonstrated positive results in the RELIEF study
August 31, 2020
·
5 min read
Joint Pain Injections Market: Investments by key players is driving the global market
Transparency Market Research has published a new report titled, “Joint Pain Injections Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.
August 31, 2020
·
5 min read
Drug Development
Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020
Arrowhead Pharmaceuticals Inc. announced the presentation of positive new Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III being developed as a treatment for patients with hypertriglyceridemia, and ARO-ANG3 targeting angiopoietin like protein 3 being developed as a treatment for mixed dyslipidemias.
August 31, 2020
·
5 min read
CLINUVEL Opens VALLAURIX R&D Centre In SingaporeBespoke Research & Development Centre to advance innovative pharmaceutical and OTC products
The CLINUVEL Group announced the opening of its state-of-the-art centralised Research & Development Centre in Singapore, operated by CLINUVEL subsidiary VALLAURIX PTE Ltd.
August 31, 2020
·
7 min read
Biotech Bay
IDEAYA to Participate in Upcoming September 2020 Investor Relations Events
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced that management will present at the following upcoming investor relations events.
August 31, 2020
·
2 min read
Drug Development
Provention Bio Announces Initiation of Phase 2b PROACTIVE Study of PRV-015 (anti-IL-15) in Non-responsive Celiac Disease
Potential to be the first approved therapeutic for the treatment of Non-responsive Celiac Disease PRV-015 (anti-interleukin-15) is the first investigational product to show both a reduction in gluten-induced symptoms and in markers of intestinal inflammation in a placebo-controlled trial in celiac subjects
August 31, 2020
·
7 min read
Biotech Bay
NeuroPace Raises $67 Million Financing to Support Commercial Expansion of the RNS® System for Refractory Epilepsy
NeuroPace Raises $67 Million Financing to Support Commercial Expansion of the RNS ® System for Refractory Epilepsy Funds will also support clinical trial to pursue new indication for the company’s life-changing neuromodulation technology MOUNTAIN VIEW, Calif.--( BUSINESS WIRE )-- NeuroPace, Inc. , a Silicon Valley-based medical technology company, today announced it has raised $67 million in a funding round led by Accelmed Partners with participatio
August 31, 2020
·
4 min read
Business
Todos Medical Announces $23,760,000 Contract for COVID-19 PCR Testing Equipment & Supplies With Wisconsin-based Laboratory
Todos Medical Ltd. (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into a sales agreement with a Wisconsin-based laboratory to supply it with the necessary testing equipment and supplies
August 31, 2020
·
5 min read
Pharm Country
AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4)
AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it will be making company presentations at two upcoming investor conferences: the 2020 H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14th at 4:30 p.m.
August 31, 2020
·
3 min read
Previous
9 of 25
Next